Clinical efficacy and safety evaluation of low molecular weight heparin combined with urokinase intravenous thrombolysis in treatment of acute myocardial infarction

Objective To evaluate the clinical efficacy and safety of low molecular weight heparin combined with urokinase intravenous thrombolysis in the treatment of acute myocardial infarction. Methods Forty-six patients with acute myocardial infarction were randomly divided into the thrombolysis group(thrombolysis re-patency group and thrombolysis non-patency group) with 23 patients and the non-thrombolysis group with 23 patients. The thrombolysis group received low molecular weight heparin combined with urokinase treatment; The non-thrombolysis group received conventional treatment, without thrombolysis treatment. The blood ejection fractions, treatment effects and mortality rates of the three groups of patients were observed. Results The 17 patients with thrombolysis re-patency(73.9%) were significantly higher than the 6 patients with thrombolysis non-patency(26.1%)(P 0.05). The total effective rate of the thrombolysis re-patency group was 88.2%, which was significantly higher than the 66.7% of the thrombolysis nonpatency group and the 65.2% of the non-thrombolysis group(P 0.05 for all). Conclusion In the treatment of acute myocardial infarction, the application of low molecular weight heparin combined with urokinase intravenous thrombolysis can effectively reduce the mortality rate, promote the re-patency rate of coronary artery and improve prognosis.